CT 01 - Clinical Trials

Presentations

• 01:00pm - 01:10pm PT

  A Double-Blinded Placebo-Controlled Biomarker Stratified Randomized Trial of Apalutamide (APA) and Radiotherapy for Recurrent Prostate Cancer (NRG GU006, BALANCE trial)

  Speaker: Daniel Spratt, MD - University Hospitals Seidman Cancer Center, Case Western Reserve University, Beachwood
• 01:10pm - 01:20pm PT

  177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer; Primary Endpoint Analysis of the Phase II LUNAR Randomized Trial

  Speaker: Amar Kishan, MD, PhD - UCLA, Culver City
• 01:20pm - 01:30pm PT

  Androgen Deprivation Therapy (ADT) and High Dose Definitive Radiotherapy (RT) +/- Whole Pelvic RT in Patients with Unfavorable Intermediate or Favorable High-Risk Prostate Cancer: Early Results of a Phase III Randomized Controlled Trial

  Speaker: Mack Roach, MD, PhD, FASTRO - University of California San Francisco, San Francisco
• 01:30pm - 01:40pm PT

  Discussant

  Speaker: Karen Hoffman, MD, FASTRO - The University of Texas MD Anderson Cancer Center, Houston
• 01:40pm - 01:50pm PT

  Toxicities and Quality of Life Following Observation or Radiation Therapy for Dupuytren's Disease in the International DEPART Randomized Trial

  Speaker: Jarad Martin, MB, ChB, PhD, DMed(Research) BSc FRANZCR GAustMS - Calvary Mater Newcastle Hospital, Newcastle
• 01:50pm - 02:00pm PT

  Clinical Effectiveness of Single Course Low-Dose Radiation Therapy in Knee Osteoarthritis: Short-term Results from the Randomized, Sham-Controlled Trial

  Speaker: Byoung Hyuck Kim, MD, PhD - Seoul National University College of Medicine, SMG-SNU Boramae Medical Center, Seoul
• 02:00pm - 02:10pm PT

  Discussant

  Speaker: Gopal Bajaj, MD, MBA, FASTRO - Inova Schar Cancer Institute, Fairfax
• 02:10pm - 02:20pm PT

  Decreasing the Dose of Consolidation Radiation Therapy in DLBCL/HGBL: A Phase II Trial by the International Lymphoma Radiation Oncology Group

  Speaker: Christopher Kelsey, MD, FASTRO - Duke University Medical Center, Durham
• 02:20pm - 02:30pm PT

  Efficacy of Hypofractionated Stereotactic Radiotherapy with Different Dose Fractionation Regimens Combined with Concurrent Bevacizumab in Recurrent High-Grade Gliomas: A Randomized Controlled Trial

  Speaker: Feng Liu, MD - Hunan Cancer Hospital, Changsha